Bioxcel Therapeutics Inc (BTAI)

04:48 AM

BioXcel Therapeutics Announces Proposed Public Offering - GlobeNewswire

04:48 AM

04:47 AM

BioXcel Therapeutics Announces Proposed Public Offering - Benzinga

04:47 AM

04:47 AM

BioXcel Therapeutics Launches Public Offering to Fund Critical Clinical Trials | BTAI Stock News - StockTitan

04:47 AM

Nov 18, 2024

BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Lags Revenue Estimates - MSN

Nov 18, 2024

Nov 15, 2024

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 15, 2024

Nov 15, 2024

BioXcel Therapeutics Inc (BTAI) Q3 2024 Earnings Call Highlights: Strategic Trials and Financial Adjustments - GuruFocus.com

Nov 15, 2024

Nov 15, 2024

BioXcel Therapeutics Inc (BTAI) Q3 2024 Earnings Call Highlights: Strategic Trials and ... By GuruFocus - Investing.com Canada

Nov 15, 2024

Nov 15, 2024

BioXcel Therapeutics Inc (BTAI) Q3 2024 Earnings Call Highlights: Strategic Trials and ... - Yahoo Finance

Nov 15, 2024

Nov 15, 2024

BioXcel Therapeutics Inc. (BTAI) Quarterly 10-Q Report - Quartzy

Nov 15, 2024

Nov 14, 2024

BioXcel Therapeutics stock hits 52-week low at $0.5 By Investing.com - Investing.com Australia

Nov 14, 2024

Nov 14, 2024

BioXcel Therapeutics Reports Q3 2024 Financial Results - TipRanks

Nov 14, 2024

Nov 14, 2024

BioXcel Therapeutics stock hits 52-week low at $0.5 - Investing.com India

Nov 14, 2024

Nov 14, 2024

Earnings call: BioXcel Therapeutics reports Q3 2024 financials - Investing.com

Nov 14, 2024

Nov 14, 2024

BioXcel Therapeutics earnings beat by $0.19, revenue fell short of estimates - Investing.com Canada

Nov 14, 2024

Nov 14, 2024

BioXcel Therapeutics Inc Reports Q3 2024 Earnings: Net Revenue a - GuruFocus.com

Nov 14, 2024

Nov 14, 2024

BioXcel Therapeutics Reports Third Quarter 2024 Financial Results - GlobeNewswire

Nov 14, 2024

Nov 14, 2024

Critical Survey: Emergent BioSolutions (NYSE:EBS) vs. BioXcel Therapeutics (NASDAQ:BTAI) - Defense World

Nov 14, 2024

Nov 13, 2024

What To Expect From BioXcel Therapeutics Inc (BTAI) Q3 2024 Earnings - GuruFocus.com

Nov 13, 2024

Nov 13, 2024

BioXcel Therapeutics (BTAI) Set to Announce Earnings on Thursday - Defense World

Nov 13, 2024

Nov 12, 2024

BioXcel advances trials for acute agitation treatments - Investing.com India

Nov 12, 2024

Nov 12, 2024

BioXcel advances trials for acute agitation treatments By Investing.com - Investing.com UK

Nov 12, 2024

Nov 12, 2024

BioXcel Therapeutics Advances Pivotal Phase 3 Trials of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders, Schizophrenia, and Alzheimer's Dementia - The Manila Times

Nov 12, 2024

Nov 12, 2024

BioXcel Therapeutics Advances Pivotal Phase 3 Trials of - GlobeNewswire

Nov 12, 2024

Nov 12, 2024

BioXcel's Phase 3 Breakthrough: First Patient Enrolled in Critical Agitation Treatment Trial | BTAI Stock News - StockTitan

Nov 12, 2024

Nov 08, 2024

BioXcel Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024 - GlobeNewswire

Nov 08, 2024

Nov 05, 2024

Will BioXcel Therapeutics, Inc. (BTAI) Report Negative Q3 Earnings? What You Should Know - MSN

Nov 05, 2024

Oct 30, 2024

ROSEN, TRUSTED AND TOP RANKED INVESTOR COUNSEL, Encourages BioXcel Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionBTAI - Marketscreener.com

Oct 30, 2024

Oct 29, 2024

BioXcel Therapeutics to Present at ThinkEquity Conference - The Manila Times

Oct 29, 2024

Oct 28, 2024

Pre-market Movers: EVOK, HCTI, GLUE, MNPR... - RTTNews

Oct 28, 2024

Oct 23, 2024

BioXcel Therapeutics (NASDAQ:BTAI) PT Lowered to $5.00 - Defense World

Oct 23, 2024

Oct 19, 2024

BioXcel announces defense grant to UNC to fund study for treating acute stress disorder - MSN

Oct 19, 2024

Oct 15, 2024

BioXcel Therapeutics partners with UNC for ASD trial By Investing.com - Investing.com Australia

Oct 15, 2024

Oct 15, 2024

BioXcel Therapeutics partners with UNC for ASD trial - Investing.com India

Oct 15, 2024

Oct 15, 2024

BioXcel Therapeutics Announces U.S. Department of Defense - GlobeNewswire

Oct 15, 2024

Oct 15, 2024

BioXcel Therapeutics Announces U.S. Department of Defense Grant to University of North Carolina to Fund Study of BXCL501 (Sublingual Dexmedetomidine) for Treating Acute Stress Disorder - StockTitan

Oct 15, 2024

Oct 10, 2024

BioXcel Therapeutics reports executive transition - Investing.com India

Oct 10, 2024

Oct 09, 2024

BioXcel Therapeutics reports executive transition By Investing.com - Investing.com Australia

Oct 09, 2024

Oct 09, 2024

Investing in BioXcel Therapeutics Inc (BTAI) Is Getting More Attractive - Knox Daily

Oct 09, 2024

Oct 04, 2024

BioXcel Therapeutics executive sells shares worth over $3,000 By Investing.com - Investing.com Australia

Oct 04, 2024

Oct 04, 2024

BioXcel Therapeutics CSO sells shares worth $3,946 By Investing.com - Investing.com South Africa

Oct 04, 2024

Oct 04, 2024

BioXcel Therapeutics executive sells shares worth $3,449 By Investing.com - Investing.com Australia

Oct 04, 2024

Oct 04, 2024

BioXcel therapeutics officer Javier Rodriguez sells shares worth $3,774 By Investing.com - Investing.com South Africa

Oct 04, 2024

Oct 03, 2024

Bioxcel therapeutics CFO sells shares worth $3,946 By Investing.com - Investing.com Canada

Oct 03, 2024

Oct 03, 2024

Bioxcel therapeutics CFO sells shares worth $3,946 - Investing.com

Oct 03, 2024

Oct 03, 2024

BioXcel Therapeutics executive sells shares worth over $3,000 - Investing.com

Oct 03, 2024

Oct 03, 2024

BioXcel Therapeutics CSO sells shares worth $3,946 - Investing.com India

Oct 03, 2024

Oct 03, 2024

BioXcel therapeutics officer Javier Rodriguez sells shares worth $3,774 - Investing.com

Oct 03, 2024